Microscopic Polyangiitis Market
Regional Analysis
Europe
Microscopic Polyangiitis Market is expected to witness significant growth
over the forecast period, owing to proposed product launches. For instance,
Bristol-Myers Squibb Company is conducting phase lll clinical trials for
Abatacept (Orencia), which is expected to be completed by September 2022.
Orencia is a recombinant protein, which inhibits the T lymphocyte activation
pathway, thereby suppressing the immune system.
Microscopic polyangiitis (MPA)
occurs due to inflammation of blood vessels resulting in damage to other
organs, mostly kidney, lungs, nerves, skin, and joints. MPA is an immune system
mediated disorder, however the exact reason leading to immune system dysfunction
is unknown. Since MPA affects multiple organs, various symptoms such as
illness, fatigue, fever, loss of weight and appetite, coughing blood in case of
lungs, and loss of sensation in case of nerves can be seen. Diagnosis involves
blood test for antineutrophil cytoplasmic antibodies (ANCA), urine test for
detection of red blood cells (RBCs), and imaging techniques such as computed
tomography (CT), magnetic resonance (MR) scan, and X-rays. If results of these
tests are positive for presence of MPA, biopsy (tissue sample testing) is
performed for confirmation of presence of MPA.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2529
Microscopic Polyangiitis Market
Drivers
In the recent past, various
regulatory bodies such as European Medicines Agency (EMA), the U.S. Food and
Drug Administration (FDA), Medicines and Healthcare products Regulatory Agency
(MHRA), and others have granted treatment related approvals. Such treatment
approvals are expected to propel the global microscopic polyangiitis market
growth over the forecast period. For instance, in October 2018, Genentech,
Inc., a San Francisco-based biotechnology company, received approval from the
U.S. Food and Drug Administration (FDA) to update the Rituxan label to include
the follow-up treatment information of adult patients suffering from
granulomatosis with polyangiitis and microscopic polyangiitis, who had shown
improvement in medical condition with the glucocorticoid and cyclophosphamide
induction treatment.
Launch of new treatment methods
by key players is expected to drive the global microscopic polyangiitis market
growth over the forecast period. For instance, in July 2018, InflaRx N.V., a
German clinical stage bio-pharmaceutical company, received an approval from the
U.S. Food and Drug Administration (FDA) for conducting phase-2 clinical trials
to assess the safety and effectiveness of IFX-1 for treatment of
anti-neutrophil cytoplasmic autoantibody (ANCA) vasculitis, presence of which
indicates that the patient is suffering from microscopic polyangiitis. IFX-1 is
an inhibitor of the complement system (a component of immune system) and
neutralizes C5a component without affecting the normal immune functions. These factors
are expected to drive the global microscopic polyangiitis market growth over
the forecast period.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/microscopic-polyangiitis-market-2529
Microscopic Polyangiitis Market
Restraints
The corticosteroids have side
effects, which include skin thinning and intense pain. The monoclonal antibody
production involves costly and time consuming research. Azathioprine involves
side effects such as diarrhea, joint pain, loss of coordination, seizure, and
vision changes. These factors are expected to restrain the global microscopic
polyangiitis market growth over the forecast period.
In March 2018, Amerigen
Pharmaceuticals Limited, a China-based generic pharmaceutical company, was
granted approval for its Abbreviated New Drug Application (‘ANDA’), by the U.S.
FDA, for its cyclophosphamide capsules 25mg and 50mg. Cyclophosphamide is an
immunosuppressive agent used for the treatment of microscopic polyangiitis in
combination with corticosteroids. This is expected to propel the Asia Pacific
microscopic polyangiitis market growth over the forecast period in turn
supporting global microscopic polyangiitis market growth.
Microscopic Polyangiitis Market
Key Players
Some of the key players operating
in the global microscopic polyangiitis market include Genentech, Inc.,
Celltrion, Inc., InflaRx N.V., ChemoCentryx Inc., Bristol-Myers Squibb Company,
Teijin Pharma Ltd, Amerigen Pharmaceuticals Limited, Sandoz International GmbH
(Novartis Division), and TTY Biopharm Company Ltd.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2529
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment